Claim 30% Off Global Market Reports With Code ONLINE30 – Insights on Tariff Effects, Global Trade, and Industry Disruptors

How Big Is The Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Today And What Is Its Future Size?

In recent years, there has been a robust expansion in the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market. This surge is anticipated to continue, rising from $5.69 billion in 2024 to $6.11 billion in 2025, boasting a compound annual growth rate (CAGR) of 7.3%. The progression observed in the historic phase can be connected to the augmented incidence of base conditions, improvement in diagnostic instruments, advancements in pharmaceuticals, and an increase in global healthcare accessibility.

Significant expansion is anticipated for the exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market in the coming years, with it projected to reach a size of “$8.21 billion in 2029, demonstrating a compound annual growth rate (CAGR) of 7.7%. The forecast period’s growth can be credited to factors such as patient education and support, regulatory shifts and reimbursement policies, as well as the advancement of telemedicine, remote monitoring, data analytics and artificial intelligence. Other key trends expected to impact the market in the forecast period include the rise of personalized treatment methods, the introduction of new therapies, less invasive diagnostic procedures, and integrative care models.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12992&type=smp

Which Growth Drivers Are Shaping The Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Outlook?

The surge in diabetes cases is forecasted to stimulate expansion in the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market. Diabetes is a long-term metabolic disorder identified by enduring high blood sugar levels (hyperglycemia), caused by inadequate insulin production or improper insulin utilization by the body. EPI therapy, especially pancreatic enzyme replacement therapy (PERT), is beneficial for nutrient assimilation in diabetic and EPI patients, besides enhancing glycemic control. For example, The National Health Service (NHS England), a UK-based government-funded healthcare organization, revealed that the figure of people identified with pre-diabetes escalated to 3,615,330 in June 2024, an 18% rise from 3,065,825 in 2023. Remarkably, among those below 40 years, cases soared nearly 25%, moving up from 173,166 in 2022 to 216,440 in 2023. Consequently, the rising diabetes count is fuelling the enlargement of the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market.

How Is The Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Categorized Across Applications And Types?

The exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market covered in this report is segmented –

1) By Therapies: Nutritional Management, Pancreatic Enzyme Replacement Therapy (PERT), Lifestyle Modifications Approach

2) By Diagnostics: Blood Tests, Magnetic Resonance Imaging (MRI), Endoscopic Ultra-Sonography (EUS), Computerized Tomography (CT) Scanning

3) By Drug Type: Generic, Branded

4) By Distribution Channel: Direct Tender, Retail Pharmacy , Third-Party Distributor, Other Distribution Channels

5) By End User: Hospitals, Specialty Clinics, Homecare, Diagnostic Center, Research And Academic Institutes, Other End Users

Subsegments:

1) By Nutritional Management: Dietary Modifications, Nutritional Supplements

2) By Pancreatic Enzyme Replacement Therapy (PERT): Capsule Formulations, Tablet Formulations, Powder Formulations

3) By Lifestyle Modifications Approach: Weight Management, Physical Activity Recommendations, Smoking Cessation Programs

How Are Market Trends Influencing Competition In The Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market?

Leading firms in the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market are employing a strategic alliance strategy to bolster technology integration and broaden their market footprint. A strategic alliance typically involves the fusion of resources, skills, and efforts of two or more companies in pursuit of mutual goals or objectives. For example, in February 2023, Codexis, Inc., a US-based firm specialized in protein engineering, and Nestlé Health Science, a Swiss firm focused on the science of nutrition, unveiled interim outcomes from their Phase 1 clinical trial of CDX-7108, a potential treatment for exocrine pancreatic insufficiency (EPI). These Phase 1 trial outcomes set the stage for further investigations that could markedly enhance treatment possibilities for patients afflicted with EPI.

Who Are The Primary Market Leaders In The Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market?

Major companies operating in the exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market are Pfizer Inc., Merck & Co. Inc., Janssen Pharmaceuticals Inc., AbbVie Inc., Novartis AG, Sanofi S.A., AstraZeneca PLC, Abott Laboratories, Medtronic PLC, Solvay S.A., Laboratory Corporation of America Holdings (Labcorp), Organon group of companies Metagenics LLC, Allergan PLC, Chiesi Farmaceutici S.p.A., Codexis Inc., Nordmark Arzneimittel GmbH & Co. KG, ChiRhoClin Inc., Digestive Care Inc., Alcresta Therapeutics Inc., Vivus Inc., Cilian AG, Bioserv Diagnostics Gmbh, Anthera Pharmaceuticals Inc., Aptalis Pharma Inc., First Wave BioPharma Inc., EagleBiosciences Inc., ScheBo Biotech AG.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/exocrine-pancreatic-insufficiency-epi-therapeutics-and-diagnostics-global-market-report

What Are The Emerging Regional Trends Driving The Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market?

North America was the largest region in the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market in 2024. The regions covered in exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=12992&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model